---
title: Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin
  Treatment
date: '2024-09-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39254740/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240911183636&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: In adults with type 2 diabetes who had not previously received
  insulin, once-weekly efsitora was noninferior to once-daily degludec in reducing
  glycated hemoglobin levels. (Funded by Eli Lilly; QWINT-2 ClinicalTrials.gov number,
  ...'
disable_comments: true
---
CONCLUSIONS: In adults with type 2 diabetes who had not previously received insulin, once-weekly efsitora was noninferior to once-daily degludec in reducing glycated hemoglobin levels. (Funded by Eli Lilly; QWINT-2 ClinicalTrials.gov number, ...